Northern Trust Corp Has $11.04 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Northern Trust Corp grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 5.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 385,157 shares of the specialty pharmaceutical company's stock after acquiring an additional 20,490 shares during the quarter. Northern Trust Corp owned about 1.19% of Collegium Pharmaceutical worth $11,035,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. New Age Alpha Advisors LLC acquired a new stake in Collegium Pharmaceutical in the fourth quarter worth about $40,000. KBC Group NV raised its position in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after buying an additional 982 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after acquiring an additional 316 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock valued at $196,000 after acquiring an additional 642 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $230,000.

Collegium Pharmaceutical Stock Up 0.4%

NASDAQ COLL traded up $0.13 during trading on Tuesday, reaching $29.96. 424,409 shares of the company's stock were exchanged, compared to its average volume of 428,831. The company's fifty day simple moving average is $28.13 and its 200-day simple moving average is $29.80. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29. The firm has a market capitalization of $962.67 million, a PE ratio of 12.91 and a beta of 0.63. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). The firm had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business's revenue for the quarter was up 22.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.45 earnings per share. Sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analysts Set New Price Targets

COLL has been the subject of a number of research reports. Piper Sandler reaffirmed a "neutral" rating and set a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. StockNews.com downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. Finally, Needham & Company LLC restated a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Collegium Pharmaceutical has a consensus rating of "Moderate Buy" and a consensus price target of $43.80.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Colleen Tupper sold 977 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the completion of the sale, the chief financial officer now directly owns 164,269 shares of the company's stock, valued at approximately $4,928,070. This trade represents a 0.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 81,693 shares of company stock worth $2,334,994. 2.51% of the stock is owned by corporate insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.